EUVIMEDEUVIMED entdecken
Crossref

Approved AI-based fluid monitoring to identify morphological and functional treatment outcomes in neovascular age-related macular degeneration in real-world routine

Virginia Mares, Ursula Margarethe Schmidt-Erfurth iD, Oliver Leingang, Philipp Fuchs, Marcio B Nehemy, Hrvoje Bogunovic, Daniel Barthelmes, Gregor S Reiter iD

British Journal of Ophthalmology · 2024-07 · 108 (7) · 971-977

DOI: 10.1136/bjo-2022-323014 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Ophthalmology, 2024-07. Verfasst von Virginia Mares und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology and Optometry, Medical University of Vienna, Vienna, Austria. Hauptthemen laut MEDLINE: Tomography, Optical Coherence, Angiogenesis Inhibitors, Visual Acuity, Intravitreal Injections. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 36 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

To predict antivascular endothelial growth factor (VEGF) treatment requirements, visual acuity and morphological outcomes in neovascular age-related macular degeneration (nAMD) using fluid quantification by artificial intelligence (AI) in a real-world cohort.

Methods

Spectral-domain optical coherence tomography data of 158 treatment-naïve patients with nAMD from the Fight Retinal Blindness! registry in Zurich were processed at baseline, and after initial treatment using intravitreal anti-VEGF to predict subsequent 1-year and 4-year outcomes. Intraretinal and subretinal fluid and pigment epithelial detachment volumes were segmented using a deep learning algorithm (Vienna Fluid Monitor, RetInSight, Vienna, Austria). A predictive machine learning model for future treatment requirements and morphological outcomes was built using the computed set of quantitative features.

Results

Two hundred and two eyes from 158 patients were evaluated. 107 eyes had a lower median (≤7) and 95 eyes had an upper median (≥8) number of injections in the first year, with a mean accuracy of prediction of 0.77 (95% CI 0.71 to 0.83) area under the curve (AUC). Best-corrected visual acuity at baseline was the most relevant predictive factor determining final visual outcomes after 1 year. Over 4 years, half of the eyes had progressed to macular atrophy (MA) with the model being able to distinguish MA from non-MA eyes with a mean AUC of 0.70 (95% CI 0.61 to 0.79). Prediction for subretinal fibrosis reached an AUC of 0.74 (95% CI 0.63 to 0.81).

Conclusions

The regulatory approved AI-based fluid monitoring allows clinicians to use automated algorithms in prospectively guided patient treatment in AMD. Furthermore, retinal fluid localisation and quantification can predict long-term morphological outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Tomography, Optical CoherenceAngiogenesis InhibitorsVisual AcuityIntravitreal InjectionsWet Macular DegenerationArtificial IntelligenceSubretinal FluidHumansMaleFemaleAgedAged, 80 and overVascular Endothelial Growth Factor ATreatment OutcomeRanibizumabFollow-Up StudiesRetrospective Studies

Stichwörter der Autor:innen

DegenerationMaculaNeovascularisationRetina

Substanzen

Angiogenesis InhibitorsVascular Endothelial Growth Factor ARanibizumab

Autor:innen und Institutionen

  • Department of Ophthalmology and Optometry, Medical University of Vienna, Vienna, Austria.
  • Department of Ophthalmology, Federal University of Minas Gerais, Belo Horizonte, Brazil.
  • Department of Ophthalmology and Optometry, Medical University of Vienna, Vienna, Austria ursula.schmidt-erfurth@meduniwien.ac.at.
  • Department of Ophthalmology, University of Zurich Faculty of Medicine, Zurich, Switzerland.
  • Department of Ophthalmology, The University of Sydney, Sydney, New South Wales, Australia.

ORCID-Profile: Ursula Margarethe Schmidt-Erfurth, Gregor S Reiter

Zitieren

APA

Mares, V., Schmidt-Erfurth, U. M., Leingang, O., Fuchs, P., Nehemy, M. B., Bogunovic, H., Barthelmes, D., & Reiter, G. S. (2024). Approved AI-based fluid monitoring to identify morphological and functional treatment outcomes in neovascular age-related macular degeneration in real-world routine. British Journal of Ophthalmology. https://doi.org/10.1136/bjo-2022-323014

Vancouver

Mares V, Schmidt-Erfurth UM, Leingang O, Fuchs P, Nehemy MB, Bogunovic H, et al. Approved AI-based fluid monitoring to identify morphological and functional treatment outcomes in neovascular age-related macular degeneration in real-world routine. British Journal of Ophthalmology. 2024. doi:10.1136/bjo-2022-323014

BibTeX
@article{Mares2024,
  author = {Mares, Virginia and Schmidt-Erfurth, Ursula Margarethe and Leingang, Oliver and Fuchs, Philipp and Nehemy, Marcio B and Bogunovic, Hrvoje and Barthelmes, Daniel and Reiter, Gregor S},
  title = {Approved AI-based fluid monitoring to identify morphological and functional treatment outcomes in neovascular age-related macular degeneration in real-world routine},
  journal = {British Journal of Ophthalmology},
  year = {2024},
  doi = {10.1136/bjo-2022-323014}
}
Kostenlos starten →